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Abstract Ceruloplasmin (CP) oxidises low density lipoprotein
(LDL). The oxidising potential depends on the formation of
Cu2+-CP which is redox-cycled during oxidation. Homocysteine
(HCY) reduces free Cu2+, potentiating its cell-damaging prop-
erty. We show that HCY enhanced LDL oxidation by CP, but
did not activate the LDL oxidising potential of Cu2+-diamine
oxidase. Selective removal of the redox-active Cu2+ abolished
the LDL oxidase activity of CP. However, HCY partially re-
stored the LDL oxidase activity of redox-copper depleted CP,
indicating that the remaining six copper atoms in CP may also
be involved in the process. Spectroscopic and oxidation inhibi-
tion studies using the Cu+-reagent bathocuproine revealed that
HCY induced Cu+-CP formation, thus promoting its LDL ox-
idase activity.
( 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The oxidative modi¢cation of low density lipoprotein
(LDL) may play an important role in the early events of
atherogenesis [1^4]. The in vivo pathophysiologically relevant
pathway(s) of atherogenic LDL alterations, however, have not
been elucidated at present. In vitro studies have shown that
LDL can be altered by a variety of biochemical reactions, e.g.
modi¢cation by endothelial cells, smooth muscle cells, peroxy-
nitrite, peroxidases, metmyoglobin, copper ions, NO radicals,
tocopheryl radicals and ceruloplasmin (CP) [5^17]. LDL oxi-
dation by free copper ions is used as a convenient system to
study anti- and pro-oxidant compounds. In this respect the
observation that the copper transport protein CP could stim-
ulate the oxidation of LDL by vascular cells in vitro has
brought an additional aspect of copper-dependent LDL oxi-
dation [18^21]. The generation of Cuþ in CP has been pro-
posed as a prerequisite of its LDL oxidising potential [22].
Recently it has been reported that homocysteine (HCY) can
reduce Cu2þ to Cuþ [23] and this reaction could potentiate the
cell-damaging property of copper ions to endothelial and neu-
ronal cells in presence of HCY [23,24]. As HCY is an inde-
pendent risk factor for atherosclerosis [25] and total plasma
HCY and copper correlate in patients with peripheral vascular
disease [26] we have tested the in£uence of HCY on the LDL
oxidising potential of CP. The results show that HCY could
enhance the oxidation of LDL by CP via the formation of
Cuþ-CP.
2. Materials and methods
CP (human) was from Calbiochem and had a purity of s 95% as
analysed by SDS^PAGE. D,L-Homocysteine, D,L-homocystine, D,L-
cysteine, D,L-methionine, bathocuproine disulphonate and diamine ox-
idase (DAO; EC 1.4.3.6, from porcine kidney, 0.07 U/mg protein)
were from Sigma-Aldrich Chemical Corp. Chelex-100 was supplied
by Bio-Rad. All other chemicals used were of analytical grade.
2.1. Lipoprotein isolation
LDL and HDL preparations were isolated by ultracentrifugation as
reported previously [27]. The ¢nal preparations were dialysed against
150 mmol/l NaCl containing 0.1 mmol/l ethylenediamine tetraacetic
acid and ¢lter-sterilised. Protein was estimated by [28] using bovine
serum albumin as a standard. All LDL concentrations are given as mg
protein/ml. Results were obtained with three di¡erent LDL prepara-
tions.
2.2. LDL oxidation
Prior to LDL oxidation, the lipoprotein was equilibrated in phos-
phate bu¡ered saline (PBS) pH 7.4 using Sephadex G-25 chromatog-
raphy (PD-10 columns, Pharmacia). LDL (0.2 mg/ml) was incubated
with the respective compound at 37‡C for 4 h.
2.3. CP preparation
Lyophilised CP was dissolved in distilled water and applied to a
small Sephadex column (Nick-column, Pharmacia) equilibrated in
PBS and the protein fraction was used in the experiments.
2.4. Estimation of LDL oxidation
Thiobarbituric acid reactive substances (TBARS) were estimated
according to [29] extending the reaction time to 45 min. A molar
extinction coe⁄cient of 156 000 mol/l/cm was used to calculate malo-
naldehyde formed.
2.5. Lipoprotein electrophoresis
Aliquots (10 Wl) of treated or untreated LDL were applied to aga-
rose gels (1% in veronal bu¡er) and run for 90 min and lipoproteins
were detected according to the supplier of the analytical system (Lip-
idophor All In, Immuno-Baxter AG). Measurement of relative elec-
trophoretic mobility (REM) was taken as an indicator of LDL oxi-
dation [30], setting the electrophoretic mobility of native (untreated)
LDL arbitrarily as 1.
2.6. Removal of redox-active copper
Redox-active copper from CP was removed according to [31] using
Chelex-100 treatment of CP in PBS for 4 h at 23‡C.
2.7. Spectroscopy
Free Cu2þ (50 Wmol/l in PBS) were incubated with 100 Wmol/l bath-
ocuproine disulphonate (BCD) in the absence or presence of 10 Wmol/l
of the respective thio-amino acid for 1 h at 37‡C and subsequently the
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spectra were recorded using a Hitachi UV/VIS 2000 spectrophotom-
eter.
CP (1.66 Wmol/l in PBS) was incubated in the absence or presence
of 100 Wmol/l thio-amino acids and 100 Wmol/l BCD for 1 h at 37‡C.
Subsequently spectra were recorded.
To avoid interactions of free Cu2þ with PBS, Cu2þ^glycine com-
plexes (molar ratio 1:6) were used according to [23].
2.8. Estimation of copper
Copper content of DAO was estimated by atomic absorption in an
aliquot of a DAO solution (10 mg/ml in 0.15 mol/l NaCl) using a
Perkin Elmer 5100 ZL atomic absorption spectrometer.
3. Results
3.1. Time course of copper ion-mediated LDL oxidation in
presence of HCY
Time course experiments with incubations up to 21.5 h
revealed that maximal stimulation of free Cu2þ (0.2 Wmol/l)
mediated LDL oxidation by HCY (100 Wmol/l) was found
between 2 and 4 h of incubation, as can be seen in Fig. 1.
Therefore all subsequent experiments were done with a stan-
dard incubation time of 4 h.
3.2. In£uence of di¡erent HCY concentrations on LDL
oxidation induced by CP
As seen in Fig. 2, HCY up to 100 Wmol/l stimulated LDL
oxidation in presence of CP (25 Wg/ml) and Cu2þ, as indicated
by increased malondialdehyde formation and alteration of the
apoprotein (see inset Fig. 2). In contrast, the LDL oxidising
potential of DAO, a copper enzyme [32] which has been
shown to stimulate endothelial cell-mediated LDL oxidation
[33], was not activated by HCY.
3.3. In£uence of HCY, homocystine (HCYin), cysteine (Cyst)
and methionine (Meth) on CP-induced LDL oxidation
From the biological thio-amino acids tested, HCY was the
only one which stimulated CP-mediated LDL oxidation. Cyst,
HCYin, and Meth showed some inhibitory action (Table 1).
HCY pretreatment of LDL (2 h at 37‡C, subsequent removal
of HCY) did not increase the susceptibility of LDL to CP-
mediated oxidation (data not shown).
3.4. E¡ect of the removal of redox-active Cu2+ on
HCY/CP-induced LDL oxidation
Table 2 shows the e¡ect of copper removal on the HCY-
stimulating e¡ect on CP-mediated LDL oxidation. Chelex
treatment of CP completely abolished the LDL oxidising
property of the protein, in accordance with [31]. Addition of
HCY (100 Wmol/l) to Chelex-treated CP still stimulated the
ability of the preparation to oxidise LDL, although LDL ox-
idation was less pronounced than with untreated CP.
3.5. CP Cu2+ reduction by HCY and e¡ect of bathocuproine
disulphonate on HCY/CP-induced LDL oxidation
Cu2þ reduction in CP may trigger the protein’s LDL oxi-
dase activity [22,31]. As seen in Fig. 3, using the Cuþ-reagent
bathocuproine disulphonate, HCY and HCYin strongly re-
duced free Cu2þ ^ indicated by the formation of the coloured
Cuþ complex (V max= 475 nm) after 1 h at 37‡C. It should be
mentioned that HCYin-mediated Cuþ formation was consid-
erably slower than that of HCY (data not shown). Cyst was
less e¡ective (20^25% of HCY), cystine and Meth had no
copper-reducing e¡ect. As seen in the inset to Fig. 3, HCY
was also able to reduce Cu2þ in CP. If Cuþ formation in CP
by HCY is a prerequisite of the stimulating e¡ect, bathocu-
proine should inhibit the HCY e¡ect on CP-mediated LDL
oxidation. As seen in Fig. 4, bathocuproine strongly inhibited
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Fig. 1. Time course of copper ion-mediated LDL oxidation in pres-
ence of HCY. LDL (0.2 mg/ml) was incubated at 37‡C in the ab-
sence or presence of HCY (100 Wmol/l) and 0.2 Wmol/l Cu2þ. Ma-
londialdehyde was measured (n=2) as given in Section 2. E, Cu2þ ;
O, Cu2þ+HCY.
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Fig. 2. In£uence of HCY on LDL oxidation induced by CP, DAO
and copper ions. LDL (0.2 mg/ml) was incubated for 4 h at 37‡C in
the absence or presence of HCY (up to 100 Wmol/l) and the respec-
tive inducer (at concentrations equivalent to 0.2 Wmol/l Cu2þ) of lip-
id oxidation. Malondialdehyde was measured (n=2) as given in Sec-
tion 2. O, DAO; E, CP; a, Cu2þ. Inset: REM of LDL treated
with CP and HCY as given above.
Table 1
In£uence of HCY, HCYin, Cyst and Meth on CP-induced LDL ox-
idation
Treatment % of control
LDL 100
LDL+CP 233
LDL+CP+HCY 728
LDL+CP+HCYin 160
LDL+CP+Meth 105
LDL+CP+Cyst 143
LDL (0.2 mg/ml) was incubated for 4 h at 37‡C in the absence or
presence of the respective amino acids (100 Wmol/l each) and CP (25
Wg/ml). Malondialdehyde was measured as given in Section 2.
Means of two measurements are given.
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the HCY-promoted LDL oxidation. Bathocuproine was by
far less e¡ective in inhibiting the CP-mediated LDL oxidation
in absence of HCY.
3.6. E¡ect of HDL on HCY/CP-induced LDL oxidation
HDL can act as an antagonist of LDL oxidative modi¢ca-
tion [34,35]. Thus we have tested the in£uence of HDL on the
enhancing e¡ect of HCY on CP-mediated LDL oxidation. As
seen in Fig. 5, the CP-mediated LDL oxidation was not af-
fected by increasing concentrations of HDL, whereas, as re-
ported previously [36], the free copper ion-mediated reaction
was strongly inhibited. HDL-depressed lipid oxidation in
HCY facilitated CP- and Cu2þ-mediated LDL oxidation
(Fig. 5).
4. Discussion
Reduction of Cu2þ to Cuþ may play a role in lipid peroxi-
dation. Cu2þ-reducing factors like lipid hydroperoxides
(Cu2þ+LOOHCCuþ+LOOc+Hþ), K-tocopherol (Cu2þ+K-
Toc-OHCCuþ+K-Toc-Oc+Hþ), ascorbic acid (Cu2þ+AscH3
CCuþ+Ascc3+Hþ) and thiols (Cu2þ+RSHCCuþ+1/2
RSSR+Hþ) have been described. For a recent review on cop-
per-dependent LDL oxidation see Burkitt [37]. Although re-
dox-active copper and iron ions had been found in atheroscle-
rotic plaques [38], the pathophysiological role of transition
metal ion-mediated LDL oxidation has been discussed con-
troversially. CP has been found to oxidise LDL in vitro [18^
22,31] qualitatively like free copper ions, an observation which
brought an in vivo aspect in the transition metal ion-mediated
LDL oxidation, although some authors have raised critical
points regarding CP-mediated lipid peroxidation due to the
extremely labile nature of this plasma protein [39,40]. Forma-
tion of Cuþ-CP by superoxide radicals may trigger the LDL
oxidation potential of the protein in cell-mediated LDL oxi-
dation systems [21]. In this respect, Feichtenhofer et al. [41]
have recently shown that ascorbate/dehydroascorbate could
activate CP as an LDL oxidase presumably by reducing the
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Fig. 3. Cu2þ-reducing activity of HCY, HCYin, Cyst, cystine and
Meth. Free Cu2þ ions (50 Wmol/l in PBS) were incubated with 100
Wmol/l BCD in the absence or presence of 10 Wmol/l of the respec-
tive thio-amino acid for 1 h at 37‡C and subsequently the spectra
were recorded. Inset: Cu2þ reduction in CP by HCY. CP (1.66
Wmol/l in PBS) was incubated with 100 Wmol/l BCD in the absence
or presence of 100 Wmol/l HCY for 1 h at 37‡C. Subsequently spec-
tra were recorded.
Table 2
E¡ect of the removal of redox-active Cu2þ on HCY/CP-induced
LDL oxidation
Treatment % of control
LDL 100
LDL+CP 448
LDL+CP+HCY 1106
LDL+CP chel 112
LDL+CP chel+HCY 438
Redox-active Cu2þ was removed from CP as given in Section 2.
LDL (0.2 mg/ml) was incubated for 4 h at 37‡C in the absence or
presence of the respective CP (25 Wg/ml) preparation (CP: untreated
CP, CP chel: redox-active Cu2þ removed). Malondialdehyde was
measured as given in Section 2. Means of two measurements are
given.
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Fig. 4. E¡ect of bathocuproine disulphonate on HCY/CP-induced
LDL oxidation. LDL (0.2 mg/ml) was incubated with CP for 4 h at
37‡C in the absence or presence of bathocuproine (100 Wmol/l) with
or without HCY (100 Wmol/l). Malondialdehyde was measured as
given in Section 2. E, CP; a, CP+HCY.
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Fig. 5. E¡ect of HDL on HCY/CP-induced LDL oxidation. LDL
(0.2 mg/ml) was incubated for 4 h at 37‡C in the absence or pres-
ence of HCY (up to 100 Wmol/l) and CP or free Cu2þ. The e¡ect of
HDL (up to 0.6 mg/ml) on LDL oxidation was studied. E, CP; a,
CP+HCY; F, free Cu2þ ; b, free Cu2þ+HCY. Malondialdehyde was
measured (n=2) as given in Section 2.
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redox-active Cu2þ in CP. HCY has been shown to reduce free
Cu2þ [23]. Thus one may assume that HCY may activate the
LDL oxidase property of CP by reducing the redox-active
Cu2þ of the protein. HCY up to 100 Wmol/l stimulated LDL
oxidation in presence of CP. In contrast, the LDL oxidising
potential of Cu2þ DAO was not activated by HCY. This may
be due to the location of the copper atom in the protein,
which ^ in contrast to CP, where the redox-active copper is
located near the surface of the protein [22] ^ may make the
access of the activator more di⁄cult. The oxidation potential
of equivalent amounts of free copper ions (0.2 Wmol/l) was
also enhanced by HCY under these conditions. Lynch et al.
[42] reported no e¡ect of HCY on free Cu2þ-mediated LDL
oxidation as assessed by agarose gel electrophoresis. These
authors used 16 h incubations (10 WM Cu2þ/1 mM HCY)
instead of 4 h as used in the present study. A time course
experiment showed that maximal stimulation of free Cu2þ
(0.2 Wmol/l) mediated LDL oxidation by HCY (100 Wmol/l)
was found between 2 and 4 h of incubation. In accordance
with the observation of Lynch, no stimulation was found
when the incubation time was prolonged up to 21.5 h.
From the biological thio-amino acids tested, HCY was the
only one which stimulated CP-mediated LDL oxidation. Cyst,
HCYin, and Meth where ine¡ective. HCY pretreatment of
LDL did not increase the susceptibility of LDL to CP-medi-
ated oxidation (data not shown). By the removal of one of the
seven copper atoms in CP ^ the redox-active one ^ by Chelex
treatment it has been shown that this preparation was unable
to stimulate in vitro LDL oxidation [31]. In accordance with
this report Chelex treatment completely abolished the LDL
oxidising property of CP in our system. However, addition
of HCY to Chelex-treated CP still stimulated the ability of
the preparation to oxidise LDL, although not as strongly as
with the untreated CP. Thus, the remaining six copper atoms
in CP may be partially involved in the HCY e¡ect on LDL
oxidation by CP. This could be due to mobilisation of redox-
active copper ions from CP by HCY resulting in facilitated
lipid oxidation, a mechanism which has been supposed for the
peroxynitrite-promoted plasma lipoprotein oxidation medi-
ated by CP [40]. Cu2þ reduction in CP may trigger the pro-
tein’s LDL oxidase activity [22,31]. HCY was able to reduce
CP-bound Cu2þ (and free Cu2þ) as spectroscopically analysed
by the formation of the Cuþ^bathocuproine complex. Addi-
tion of bathocuproine to the CP/HCY/LDL system resulted in
strong inhibition of lipid oxidation. In contrast, bathocu-
proine was less e¡ective in inhibiting the CP-mediated LDL
oxidation in absence of HCY. Thus, Cu2þ reduction in CP by
HCY may be a prerequisite of the stimulating e¡ect. The
exact reason for the increase in CP-mediated LDL oxidation
found at low bathocuproine concentrations is not known. In
this respect Pinchuk et al. [43] reported that the Cuþ chelators
neocuproine and bathocuproine at certain chelator/copper ra-
tios could even stimulate LDL oxidation. Although HCYin
was able to reduce Cu2þ to the same extent as HCY, HCYin
did not stimulate the CP-mediated LDL oxidation. This could
be due to the molar ratio of copper ions/thio-amino acids, as
has been reported by Heinecke et al. [44] for the in£uence of
e.g. glutathione and HCY on Cu2þ-mediated LDL oxidation.
HDL can act as an antagonist of LDL-oxidative modi¢cation
[34,35]. In contrast to free copper ions HDL did not a¡ect the
CP-mediated LDL oxidation. HDL has been shown to lose its
property to protect LDL against oxidative modi¢cation by
endothelial cells in presence of CP [45,46], presumably by
binding of CP to HDL and inactivating associated paraoxo-
nase. The stimulating e¡ect of HCY on lipid oxidation was
counteracted by HDL supporting HDL as an antiatherogenic
factor [34,35].
The results show that HCY facilitates the lipid-oxidising
potential of CP. Reduction and release of Cu2þ in CP may
be a mechanism by which HCY stimulates LDL oxidation by
this acute phase protein.
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